IPSCNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Century Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$1.47+0.10 (+7.30%)
Close on Oct 19, 2026
- Market cap
- $302.49M
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2019 to 2025
Operating margin
-15.8%
Net margin
-8.8%
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +1556.8% | +175.9% | – | – |
Returns and balance sheet
7 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2019 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | 54.0% | -6.0% | |
| Return on assets | – | – | -3.3% | |
| Current ratio | – | 6.51 | 5.97 | |
| Debt to equity | – | -0.09 | – | |
| Interest coverage | – | -141.5× | – | |
| Capex to revenue | – | – | 0.8% | |
| Diluted shares | – | 7M | 87M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Century Therapeutics generated $405.41M from operations and spent $90.31M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$405.41M
Used
$90.31M
Capital expenditure$90.31M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-8.8%
×Asset turnover0.38×
×Equity multiplier1.80×
=Return on equity, FY2025-6.0%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -8.8% | 0.38× | 1.80× | -6.0% |
| FY2024 | -1920.9% | 0.02× | 2.06× | -73.1% |
| FY2023 | -6115.1% | 0.01× | 1.74× | -56.1% |
| FY2022 | -2518.4% | 0.01× | 1.32× | -37.5% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
3of 7 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$9.58M
- Cash generatingOperating cash flow above zero-$103.88M
- Return on assets improvedROA up on the prior year-35.1% → -2.7%
- Earnings backed by cashOperating cash flow above net income-$103.88M vs -$9.58M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose1.50 → 5.97
- No dilutionShare count did not rise79M → 87M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose0.02 → 0.31